安罗替尼治疗四肢韧带样纤维瘤有效性和安全性的回顾性研究

Efficacy and safety of anlotinib for patients with extremity desmoid-type fibromatosis:a retrospective study

目的:评估安罗替尼在四肢韧带样纤维瘤(desmoid-type fibromatosis,DF)患者治疗中的有效性和安全性。方法:回顾性分析2019年1月至2020年4月于四川大学华西医院接受安罗替尼治疗的26例四肢DF患者的临床及随访资料。结果:26例患者均定期随访,中位随访时间为14(11.75~16)个月。随访期间,无完全缓解(complete respons,CR)患者,10例(38.5%)部分缓解(partial response,PR),12例(46.1%)疾病稳定(stable disease,SD),4例(15.4%)疾病进展(progressive disease,PD)。疾病控制率(disease control rate,DCR)为84.6%(22/26),客观缓解率(objective response rate,ORR)为38.5%(10/26)。6个月和12个月的无进展生存期(progression-free survival,PFS)分别为92.3%和84.6%。18例(69.2%)肿瘤体积缩小,22例(84.6%)肿瘤病灶核磁共振T2(magnetic resonance imaging T2,MRIT2)信号值降低,22例(84.6%)疼痛减轻,19例(73.1%)肿瘤邻近关节活动度改善。所有患者对安罗替尼不良反应均可耐受。结论:安罗替尼对于四肢DF具有一定的疗效,可显著延缓疾病进展,提高患者生存质量,且患者对其不良反应可耐受。

Objective:To evaluate the efficacy and safety of anlotinib in patients with extremity desmoid-type fibromatosis(DF).Methods:Clinical and follow-up data of 26 patients with extremity DF who received anlotinib between January 2019 and April 2020 in West China Hospital were retrospectively analyzed.Results:All the 32 patients were followed up regularly with a median follow-up of 14(11.75-16)months.At last follow-up,none of the patients achieved a complete response(CR),but ten patients(38.5%)achieved a partial response(PR)and twelve patients(46.1%)achieved stable disease(SD),four patients(15.4%)developed progressive disease(PD)and the 6-,12-month progression-free survival(PFS)rates were 92.3%,84.6%respectively.The disease control rate(DCR)was 84.6%(22/26)and the objective response rate(ORR)was 38.5%(10/26).Meanwhile,a reduction in tumor size was achieved in eighteen patients(69.2%),a decrease in T2-weighted signal intensity on magnetic resonance imaging(MRIT2)was observed in 22 patients(84.6%),a subjective diminishment in local pain was described in 25 patients(96.2%),and an improvement in the range of motion of adjacent joints was examined in nineteen patients(73.1%)after anlotinib treatment.Additionally,anlotinib-induced toxicities were tolerated for all patients with extremity DF.Conclusions:Anlotinib was effective against extremity DF and significantly slowed the disease progression to finally improve the quality of patients’life with an acceptable drug-related toxicity.